The Federal Trade Commission, or FTC, sued the company over its role as a pharmacy benefit manager. These companies act as middlemen between drug makers, insurance plans, and pharmacies. The government alleged that Express Scripts used business practices that drove up the price of insulin. According to the FTC, the company preferred drugs with high list prices because they came with larger rebates. While these rebates benefited the middleman, they often led to higher costs for patients whose insurance payments were based on the original high price.
